This early-stage study tested whether a new vaccine called AV-1959R is safe for healthy adults aged 40-60. Sixteen participants received either the vaccine or a placebo injection to check for side effects and measure immune response. The goal is to see if the vaccine can safely t…
Phase: PHASE1 • Sponsor: Nuravax, Inc. • Aim: Prevention
Last updated Apr 01, 2026 14:41 UTC